National Resh Corp Stock Price, News & Analysis

NRC Health has introduced a new digital solution called Compliment Sharing aimed at alleviating burnout and enhancing morale among frontline healthcare teams. This tool leverages Natural Language Processing (NLP) to efficiently gather positive patient feedback and deliver it to healthcare staff in real-time. Helen Hrdy, NRC Health's Chief Growth Officer, emphasizes the importance of recognizing the efforts of healthcare workers. The system is designed for ease of use, allowing staff to send positive comments quickly, thereby fostering a culture of appreciation within healthcare systems. Most NRC Health partners can incorporate Compliment Sharing into their existing services.

NRC Health is enhancing healthcare delivery with its new tool MyView, which integrates patient insights into electronic health records (EHR) to streamline care teams' workflows. This innovation allows healthcare providers to obtain essential patient information quickly, taking only 15 seconds to review. MyView aims to foster personalized care experiences and improve communication between providers and patients. Paired with MyStory, which captures patient-generated data, it provides a comprehensive view of patient needs. NRC Health is recognized as a leader in patient experience improvement, recently ranked #1 in the 2023 Best in KLAS report.

NRC Health released its 2023 Experience Perspective, highlighting insights from over 300 healthcare leaders and 300,000 consumer surveys. The report emphasizes the importance of Human Understanding in improving patient experience and loyalty. Key findings include that only 38% of patients felt uniquely treated, despite this being crucial for Net Promoter Score. The report identifies fundamental strategies for enhancing healthcare experiences and underscores the significance of patient perspectives on quality. It also addresses the need for equity in care and outlines trends for healthcare leaders to consider in order to strengthen organizational performance.

National Research Corporation (NRC) reported 7% year-over-year revenue growth for 2022, driven by its Human Understanding Program. The company added notable clients like St. Bernards Healthcare and received the Best in KLAS 2023 Award for Patient Experience Improvement. However, revenue growth was partially offset by the phase-out of Canadian operations. For 2022, NRC allocated $12.2 million for innovation, $21.0 million for dividends, and $27.6 million for share repurchases. Diluted earnings per share fell to $1.27 for the year from $1.46 in 2021, highlighting financial challenges amidst strategic investments.

National Research Corporation (NASDAQ:NRC) has announced a quarterly cash dividend of $0.12 per share, payable on April 14, 2023. Shareholders of record as of March 31, 2023 will be eligible for this payment. With over 40 years in the healthcare sector, NRC Health focuses on enhancing customer experiences in healthcare organizations. Their approach emphasizes empathy, proprietary methods, and skilled associates to elevate patient and staff satisfaction while fostering loyalty.

National Research Corporation (NASDAQ:NRC) announced an online web simulcast of its 2022 fourth quarter earnings conference call, scheduled for February 15, 2023, at 11:00 a.m. Eastern Time. Results will be released after market close on February 14, 2023. A 30-day online replay will be available post-broadcast. The webcast can be accessed at this link. NRC Health, with over 40 years of experience, focuses on enhancing healthcare organizations' understanding of their customers to improve experiences and foster trust.

NRC Health (NASDAQ:NRC) has declared a quarterly cash dividend of $0.12 per share, payable on January 13, 2023. Shareholders of record by December 30, 2022 will receive this payment. NRC Health focuses on enhancing patient experiences and relationships in healthcare, utilizing proprietary methods and a holistic approach.

NRC Health reported its third-quarter 2022 results, revealing revenue of $37.7 million, slightly down from $37.8 million in Q3 2021. The company’s net income declined to $8.3 million from $9.7 million year-over-year, leading to a decrease in diluted earnings per share, which fell to $0.33 from $0.38. Despite revenue growth from core offerings, the overall revenue was flat due to the phasing out of Canadian operations and a decline in non-core offerings. Increased operating expenses were attributed to investments in innovation and marketing. Dividends paid amounted to $5.9 million.